RecruitingPhase 2Phase 3NCT05181748

Autologous Platelet Rich Plasma Intraovarian Infusion for Poor Responders

Investigating the Efficiency of Autologous Platelet Rich Plasma Intraovarian Infusion on Improving Ovarian Functionality in Poor Ovarian Response Patients

Sponsor

Genesis Athens Clinic

Enrollment

100 participants

Start Date

Jan 23, 2019

Study Type

INTERVENTIONAL

Conditions

Infertility, Female Ovary; Anomaly Reproductive Sterility Poor Response to Ovulation Induction Ovarian Insufficiency Ovarian Failure

Summary

Autologous platelet rich plasma (PRP) intraovarian infusion may improve ovarian response to controlled ovarian stimulation as well as the hormonal profile of poor ovarian response infertile women subjected to intracytoplasmic sperm injection (ICSI) treatment.

Eligibility

Sex: FEMALEMin Age: 35 YearsMax Age: 47 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Autologous platelet rich plasma for people with infertility, female, ovarian failure, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 35 Years to 47 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALAutologous platelet rich plasma

Preparation of PRP will be performed immediately following blood sample collection. Blood samples will be collected from the median antebrachial vein. PRP will be prepared according to the manufacturer's instructions employing a Regen Autologous Cellular Regeneration (ACR®-C) Kit (Regen Laboratory, Le Mont-sur-Lausanne, Switzerland). Approximately 60 mL of the patient's peripheral blood will be required in order to yield the required volume of PRP. The goal concentration of platelets in PRP is approximately 1.000.000 platelets/µL. The technique of PRP intraovarian infusion resembles the transvaginal paracentesis performed during the oocyte pick-up procedure. Briefly, both ovaries are visualized via transvaginal ultrasound monitoring, and they are intramedullary injected on multiple sites using a 17-gauge single lumen needle, with the patient under inhaled minimal sedation.